Luis M. Moura *

Autor invitado por SIIC

REGRESSÂO OU NÃO PROGRESSÃO DA ESTENOSE AÓRTICA OBTIDA COM TERAPÊUTICA COM ROSUVASTATINA

A terapêutica com inibidores da HMG CoA reductase (estatinas) em doentes com estenose valvular aórtica moderada assintomática e dislipidemia, tratados de acordo com as recomendações do NCEP-ATP III, determina uma menor progressão da doença avaliada por ecocardiografia num seguimento de 1.5 anos.


*Luis M. Moura
describe para SIIC los aspectos relevantes de su trabajo
O PAPEL DAS ESTATINAS NA ESTENOSE VALVULAR AÓRTICA CALCIFICADA
Institución principal de la investigación
*Hospital Pedro Hispano, Faculdade de Medicina do Porto, Oporto, Portugal
Imprimir nota

Referencias bibliográficas
1. Carabello BA. Clinical practice. Aortic stenosis. N Engl J Med 346(9):677-82, 2002.

2. Stewart BF, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29(3):630-4, 1997.

3. Otto CM, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341(3):142-7, 1999.

4. Ross J Jr, BraunwaldE. Aortic stenosis. Circulation 38(1 Suppl):61-7, 1968.

5. Ross J Jr, Linhart JW, Brauwald E. Effects of changing heart rate in man by electrical stimulation of the right atrium. Studies at rest, during exercise, and with isoproterenol. Circulation 32(4):549-58, 1965.

6. Aronow WS, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88(6):693-5, 2001.

7. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111(24):3316-26, 2005.

Otros artículos de Luis M. Moura

Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49(5):554-561, 2007.

Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. Circulation 114[(18):Suppl II] II-715, 2006.

Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. Eur J Echocardiography 7(Suppl1):174, 2006.

Moura LM, Zamorano JL, Ramos SF et al. Effects of statin therapy in aortic stenosis progression. J Am Coll Cardiol 45(3):358A, 2005.

Moura LM, Zamorano JL, Ramos SF et al. Effects of statins on soluble CD40 ligand, high sensitive C-reactive protein and interlueukin-6 levels in patients with aortic stenosis: establishing a cause effect relationship. Eur Heart J 26(Suppl):384, 2005.

Moura LM, Zamorano JL, Ramos SF et al. Rosuvastatin affecting aortic valve endothelium (RAAVE) to slow the progression of aortic stenosis. Circulation 112(Suppl II):II-117, 2005.

Para comunicarse con Luis M. Moura mencionar a SIIC como referencia:
luismoura@mail.telepac.pt

---

Acerca del trabajo completo

REGRESSÂO OU NÃO PROGRESSÃO DA ESTENOSE AÓRTICA OBTIDA COM TERAPÊUTICA COM ROSUVASTATINA

Título original en castellano
PAPEL DAS ESTATINAS NA ESTENOSE AORTICA. MITO OU REALIDADE?

Autor
Luis M. Moura¹
1 Medico, Hospital Pedro Hispano, Faculdade de Medicina do Porto, Oporto, Portugal, Consultor

Acceso a la fuente original
Revista Portuguesa de Cardiologia
http://www.spc.pt

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades